Cinnamic Acid

Dosage for Cinnamic Acid varies significantly based on the intended use.

For Allergy Patch Testing

• Standard Concentration: Typically applied as a 1% concentration in petrolatum.
• Application: A small amount is applied to the skin (usually the back) under an occlusive dressing for 48 hours. The site is then evaluated by a clinician at 48 and 96 hours.

For Nitrogen Binding (Off-label/Specialized Use)

• Typical Range: 250 mg to 1000 mg administered two to three times daily.
• Titration: Dosing often begins at the lower end of the spectrum and is adjusted based on serum ammonia levels and patient tolerance.

Cinnamic Acid use in pediatric populations is primarily limited to diagnostic allergy testing and specific metabolic disorders.

• Diagnostic Use: The concentration used for patch testing in children is often the same as in adults (1%), though the surface area of application may be reduced.
• Metabolic Use: Dosage is strictly calculated based on Body Surface Area (BSA) or weight (e.g., 100-200 mg/kg/day).
• Safety Note: Use in children under the age of 6 for immunotherapy requires extreme caution and is generally reserved for severe cases where alternative treatments have failed.

Renal Impairment

Since Cinnamic Acid is primarily excreted by the kidneys as hippuric acid, patients with a Glomerular Filtration Rate (GFR) below 30 mL/min/1.73m² may require a 50% dose reduction. Frequent monitoring of renal function and serum metabolites is mandatory.

Hepatic Impairment

In patients with severe hepatic impairment (Child-Pugh Class C), the conversion of Cinnamic Acid to benzoic acid may be slowed. While no specific dosing guidelines exist, clinicians should monitor for signs of toxicity and adjust doses based on clinical response.

Elderly Patients

Elderly patients often have decreased renal reserve. Dosing should be initiated at the low end of the adult range. Clinicians should be particularly mindful of the potential for increased sensitivity to the estrogenic effects of the compound in post-menopausal women.

Oral Administration

• Timing: Should be taken with or immediately after meals to minimize gastrointestinal upset.
• Consistency: Take the medication at the same time each day to maintain stable plasma levels.
• Preparation: Capsules should be swallowed whole. If using a powder form, it must be dissolved completely in water or juice as directed by a pharmacist.

Topical/Diagnostic Use

• Preparation: Ensure the skin is clean and dry. Avoid applying topical steroids to the test site for at least two weeks prior to testing.
• Activity: Avoid heavy sweating or showering that may loosen the patch during the 48-hour diagnostic period.

Storage

Store Cinnamic Acid products at controlled room temperature (20°C to 25°C / 68°F to 77°F). Protect from light and moisture. Keep all containers tightly closed.

If a dose is missed, it should be taken as soon as remembered. However, if it is nearly time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not double the dose to catch up, as this increases the risk of metabolic acidosis or gastrointestinal distress.

Signs of acute Cinnamic Acid overdose may include:

• Severe nausea and vomiting
• Metabolic acidosis (rapid breathing, confusion, lethargy)
• Tinnitus (ringing in the ears)
• Skin flushing or severe hives

In the event of a suspected overdose, contact a Poison Control Center or seek emergency medical attention immediately. Treatment is primarily supportive, focusing on correcting acid-base imbalances and ensuring adequate hydration for renal clearance.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop the medication without medical guidance, as this could lead to a rebound in ammonia levels or an incomplete diagnostic profile.

Cinnamic Acid is generally well-tolerated when used in diagnostic concentrations, but systemic or prolonged use can lead to the following:

• Contact Dermatitis: Redness, itching, and small blisters at the site of application. This is the most common reaction during diagnostic testing and typically resolves within a few days of patch removal.
• Gastrointestinal Upset: When taken orally, patients frequently report dyspepsia (indigestion), mild nausea, or abdominal cramping.
• Flavor Alteration: A lingering spicy or bitter taste in the mouth may occur shortly after oral administration.

• Photosensitivity: Increased sensitivity to sunlight, resulting in an exaggerated sunburn response. Patients should use protective clothing and sunscreen.
• Headache: Mild to moderate tension-type headaches that usually dissipate as the body adjusts to the medication.
• Diarrhea: Loose stools may occur, particularly with higher doses used for nitrogen binding.

• Metabolic Acidosis: A serious condition where the blood becomes too acidic. Symptoms include deep, rapid breathing (Kussmaul breathing) and extreme fatigue.
• Urticaria (Hives): Generalized skin rash that may indicate a systemic allergy to the compound.
• Elevated Liver Enzymes: Transient increases in AST or ALT levels, requiring monitoring.

> Warning: Stop taking Cinnamic Acid and call your doctor immediately if you experience any of these serious reactions:

• Anaphylaxis: This is a life-threatening allergic reaction. Symptoms include swelling of the face, lips, or tongue; difficulty breathing; wheezing; a rapid, weak pulse; and fainting.
• Severe Skin Peeling: Conditions such as Stevens-Johnson Syndrome (SJS) have been rarely associated with aromatic acids. Look for flu-like symptoms followed by a painful red or purplish rash that spreads and blisters.
• Neurological Changes: Sudden confusion, tremors, or seizures, which may indicate an electrolyte imbalance or a failure in nitrogen scavenging efficacy.
• Hematuria: Blood in the urine, which may signal renal irritation or crystallization of metabolites.

• Bone Mineral Density Changes: Due to its weak estrogen receptor agonism, long-term use may theoretically influence bone turnover, though clinical data in humans is currently limited.
• Hormonal Imbalance: Prolonged exposure to high doses may interfere with the endogenous endocrine system, potentially leading to menstrual irregularities in women or gynecomastia (breast tissue growth) in men.
• Renal Stress: Chronic excretion of high levels of hippuric acid can place a burden on the renal tubules, potentially leading to interstitial nephritis over several years of therapy.

Currently, there are no FDA Black Box Warnings specifically for Cinnamic Acid as a standalone agent. However, when Cinnamic Acid is a component of Non-Standardized Allergenic Extracts, a general warning applies regarding the risk of severe systemic reactions, including anaphylaxis. These products must only be administered by healthcare professionals prepared to manage life-threatening allergic emergencies.

Report any unusual symptoms or persistent side effects to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.

Cinnamic Acid is a potent biological and chemical agent. Patients must be aware that its use in allergy testing can induce a systemic allergic flare in highly sensitive individuals. Always inform your clinician if you have a known allergy to cinnamon, Balsam of Peru, or synthetic fragrances before exposure to Cinnamic Acid.

No FDA black box warnings for Cinnamic Acid. However, users of Cinnamic Acid-containing allergenic extracts should refer to the class-wide warnings for allergenic extracts regarding the risk of anaphylaxis and the necessity of medical supervision during administration.

Allergic Reactions / Anaphylaxis Risk

There is a significant risk of cross-reactivity. Patients allergic to Cinnamic Acid may also react to cinnamaldehyde, cinnamon oil, and various benzoates. If you experience systemic itching, throat tightness, or lightheadedness after application or ingestion, seek emergency care.

Renal and Hepatic Monitoring

Because the kidneys are the primary route of elimination, patients with pre-existing renal disease are at a higher risk for toxicity. Similarly, hepatic function is required for the metabolic conversion of Cinnamic Acid. Regular monitoring is essential for patients on long-term therapy.

Estrogenic and Corticosteroid Effects

Due to its MoA as an estrogen and corticosteroid receptor agonist, Cinnamic Acid should be used with caution in patients with hormone-sensitive cancers (such as breast or uterine cancer) or those with conditions that may be exacerbated by steroid use (such as peptic ulcer disease or severe hypertension).

Patients taking Cinnamic Acid for nitrogen binding or chronic conditions should undergo the following tests:

• Serum Ammonia: To ensure the drug is effectively lowering nitrogen levels.
• Basic Metabolic Panel (BMP): To monitor kidney function (Creatinine/BUN) and acid-base balance (Bicarbonate).
• Liver Function Tests (LFTs): To ensure the liver is processing the acid correctly.
• Skin Checks: For patients undergoing patch testing, the site must be monitored for delayed reactions up to 7 days post-application.

Cinnamic Acid generally does not cause drowsiness. However, if you experience dizziness or confusion (which may be a sign of metabolic changes), do not drive or operate heavy machinery until you have consulted your doctor.

Alcohol should be avoided or strictly limited while taking Cinnamic Acid. Alcohol can irritate the gastrointestinal lining, potentially worsening the side effects of Cinnamic Acid. Furthermore, alcohol metabolism can interfere with the liver's ability to process aromatic acids, increasing the risk of side effects.

Do not stop taking Cinnamic Acid suddenly if you are using it for nitrogen binding. Sudden discontinuation can lead to a rapid and dangerous rise in serum ammonia levels (hyperammonemic crisis). If discontinuation is necessary, your doctor will provide a tapering schedule and monitor your ammonia levels closely.

> Important: Discuss all your medical conditions, including any history of asthma, kidney disease, or hormonal disorders, with your healthcare provider before starting Cinnamic Acid.

• Sodium Benzoate / Sodium Phenylbutyrate: Using Cinnamic Acid alongside other nitrogen scavengers can lead to an additive effect that may cause severe metabolic acidosis. This combination should be avoided unless specifically managed by a metabolic specialist.
• Cisplatin: There is a theoretical risk that Cinnamic Acid may interfere with the renal clearance of platinum-based chemotherapy agents, increasing the risk of nephrotoxicity.

• Diuretics (e.g., Furosemide, Hydrochlorothiazide): Diuretics can affect the renal excretion of Cinnamic Acid metabolites. Additionally, the combination may increase the risk of dehydration and subsequent renal strain.
• Corticosteroids (e.g., Prednisone): Since Cinnamic Acid has corticosteroid receptor agonist activity, concurrent use with systemic steroids may lead to additive side effects, such as increased blood sugar or suppressed immune function.
• Hormone Replacement Therapy (HRT) / Oral Contraceptives: The estrogenic activity of Cinnamic Acid may interfere with the efficacy or increase the side effects of estrogen-containing medications.

• NSAIDs (e.g., Ibuprofen, Naproxen): Both NSAIDs and Cinnamic Acid can be irritating to the stomach lining. Concurrent use increases the risk of gastritis or peptic ulcers.
• Warfarin: Aromatic acids can occasionally displace warfarin from albumin binding sites, potentially increasing the International Normalized Ratio (INR) and the risk of bleeding. Close monitoring of coagulation parameters is advised.

• Cinnamon and Related Spices: Consuming large amounts of cinnamon, cassia, or Balsam of Peru-containing foods (like certain sodas or candies) can lead to an 'additive' exposure, increasing the likelihood of an allergic reaction or gastrointestinal upset.
• High-Protein Meals: For patients using Cinnamic Acid as a nitrogen binder, high protein intake increases the production of ammonia, which may overwhelm the drug's scavenging capacity. A low-protein diet is often recommended.

• St. John’s Wort: May induce metabolic pathways that could theoretically reduce the half-life of Cinnamic Acid, though the clinical significance is likely low.
• Vitamin C Supplements: While Cinnamic Acid is classified as a Vitamin C [EPC], taking high-dose ascorbic acid supplements may acidify the urine, potentially altering the excretion rate of hippuric acid.

• Urinary Ketone Tests: Cinnamic Acid metabolites may cause a false-positive result on certain urine dipstick tests for ketones.
• Hippuric Acid Screening: Occupational exposure tests for toluene (which also produces hippuric acid) will be invalidated by the use of Cinnamic Acid.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Maintain an up-to-date list to share with all your healthcare providers.

Cinnamic Acid must NEVER be used in the following circumstances:

• Severe Hypersensitivity: Patients with a documented history of anaphylaxis to Cinnamic Acid, cinnamaldehyde, or Balsam of Peru.
• Severe Metabolic Acidosis: Because Cinnamic Acid is metabolized into acids, it can worsen pre-existing acidosis, potentially leading to coma or death.
• Advanced Renal Failure (Anuria): If the kidneys cannot produce urine, the metabolites of Cinnamic Acid will build up to toxic levels rapidly.

Conditions requiring careful risk-benefit analysis include:

• Peptic Ulcer Disease: The acidic nature of the compound may exacerbate gastric erosions.
• Asthma: Some patients with 'aspirin-triad' or fragrance sensitivities may experience bronchospasm when exposed to aromatic acids.
• Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus (see Special Populations).
• Hormone-Dependent Tumors: Due to weak estrogenic activity, caution is advised in patients with a history of ER-positive breast cancer.

Patients should be aware of potential cross-reactivity with:

• Benzoates (common food preservatives)
• Fragrance Mix I and II
• Clove oil (Eugenol)
• Tolu balsam

> Important: Your healthcare provider will evaluate your complete medical history, including any rare metabolic disorders, before prescribing or administering Cinnamic Acid.

Cinnamic Acid is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have shown that high doses of aromatic acids can cross the placental barrier.

• First Trimester: Avoid use unless absolutely necessary for life-threatening hyperammonemia.
• Late Pregnancy: There is a theoretical risk of metabolic acidosis in the neonate if the mother is taking high doses near the time of delivery.
• Fertility: No data suggests Cinnamic Acid impairs human fertility, though its estrogenic activity warrants caution in patients undergoing IVF (In-Vitro Fertilization).

It is unknown whether Cinnamic Acid or its metabolites are excreted in human milk. Because many low-molecular-weight organic acids do pass into breast milk, caution should be exercised. If a nursing mother must take Cinnamic Acid, the infant should be monitored for signs of gastrointestinal distress or skin rashes. A risk-benefit assessment by a pediatrician is recommended.

Cinnamic Acid is used in children for diagnostic allergy testing and management of specific urea cycle disorders.

• Safety: Standardized patch testing is considered safe in children over 2 years of age.
• Growth: There is no evidence that short-term or diagnostic use affects growth. However, long-term use of any agent with corticosteroid-like activity requires monitoring of growth velocity by a pediatrician.

Clinical studies of Cinnamic Acid did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

• Renal Clearance: Dose selection should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.
• Polypharmacy: Elderly patients are often on multiple medications (e.g., diuretics, ACE inhibitors) that can interact with Cinnamic Acid’s renal excretion.

In patients with moderate renal impairment (CrCl 30-60 mL/min), the half-life of the primary metabolite, hippuric acid, is doubled.

• Dosing: Reduce the total daily dose by 25-50%.
• Dialysis: Cinnamic Acid and its metabolites are likely dialyzable, though specific clearance rates during hemodialysis have not been established. Supplemental doses after dialysis may be required.

In patients with hepatic cirrhosis, the conjugation of benzoic acid (a metabolite of Cinnamic Acid) with glycine may be impaired.

• Monitoring: Monitor for symptoms of 'benzoate toxicity,' such as CNS depression or tremors.
• Adjustment: No specific dose adjustment is provided in labeling, but close clinical supervision is required.

> Important: Special populations require individualized medical assessment and frequent laboratory follow-up to ensure safety and efficacy.

Cinnamic Acid functions as a multi-target ligand. In its role as a Nitrogen Binding Agent, it undergoes mitochondrial beta-oxidation to form benzoic acid. This intermediate then reacts with glycine to form hippuric acid, a process that consumes a nitrogen atom. This bypasses the traditional urea cycle, providing an alternative pathway for nitrogen excretion.

As an Estrogen Receptor Agonist, the phenylpropenoic acid structure mimics the A-ring of steroidal estrogens, allowing it to fit into the ligand-binding domain of ER-alpha and ER-beta. Its Corticosteroid Hormone Receptor Agonism is mediated through the modulation of NF-kappaB signaling pathways, which reduces the production of pro-inflammatory cytokines.

• Onset of Action: For nitrogen binding, reductions in serum ammonia can be observed within 2-4 hours of oral administration. For allergy testing, the immunological 'onset' (sensitization) takes 48-72 hours.
• Duration: The effects on nitrogen levels last approximately 6-8 hours per dose.
• Tolerance: There is no evidence of pharmacological tolerance developing with long-term use, although the body's glycine stores may become depleted with very high doses.

| Parameter | Value |

|---|---|

| Bioavailability | 85% - 90% (Oral) |

| Protein Binding | 70% - 80% (Albumin) |

| Half-life | 1 - 3 hours |

| Tmax | 0.5 - 1.5 hours |

| Metabolism | Hepatic (Beta-oxidation to Benzoic Acid) |

| Excretion | Renal (>90% as Hippuric Acid) |

• Molecular Formula: C9H8O2
• Molecular Weight: 148.16 g/mol
• Solubility: Slightly soluble in water; freely soluble in ethanol and oils.
• Structure: Consists of a benzene ring substituted with an acrylic acid group. It exists primarily in the trans configuration in pharmaceutical preparations.

Cinnamic Acid is a member of the phenylpropanoid family. It is chemically related to other aromatic acids like ferulic acid and caffeic acid. Within the therapeutic landscape, it is grouped with other nitrogen scavengers like sodium phenylbutyrate and allergenic extracts used in clinical immunology.